Full Press Release Details
Results of 2024 Annual General
AUSTRALIA AND SAN FRANCISCO, USA - 22 November 2024: In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations
Act 2001 (Cth), the attached information is provided in relation to the resolutions passed by the shareholders of Alterity Therapeutics
(ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") at its Annual General Meeting held on 22 November 2024.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical
stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's
lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical
trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat
the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For
further information please visit the Company's web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorised by David
Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Remy Bernarda remy.bernarda@iradvisory.com
Forward Looking Statements
This press release contains
"forward-looking statements" within the meaning of section 27A of the identify such forward-looking statements by use of such
words as "expects," "intends," "hopes," "anticipates," "believes," "could,"
"may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive
means of identifying such statements.
Important factors that could
cause actual results to differ materially from those indicated by such forward- looking statements are described in the sections titled
"Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form 20-F as well as
reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including,
but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but
not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including,
but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory
approval, production and marketing of the Company's drug components, including, but not limited to, ATH434, the ability of the Company
to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's
drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining
patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company's
patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement
made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is
made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or otherwise.
| Disclosure of Proxy Votes Alterity Therapeutics Limited Annual General Meeting Friday, 22 November 2024 | |
| GPO Box 5193, Sydney, NSW 2001 | |
| P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) | |
| F +61 (0)2 8583 3040 E hello@automic.com.au | |
| ABN 27 152 260 814 |
In accordance with section 251AA of the Corporations Act 2001, the
following information is provided in relation to resolutions put to members at the meeting.
| Proxy Votes | Poll Results (if applicable) | Results | ||||||||
| Resolution | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | FOR | AGAINST | ABSTAIN | PROXY'S DISCRETION | FOR | AGAINST | ABSTAIN | OUTCOME |
| 1 Non-binding resolution to adopt Remuneration Report | P | 360,278,902 | 247,282,902 68.64% | 87,766,213 24.36% | 27,512,053 | 25,229,787 7.00% | 272,623,588 75.65% | 87,766,213 24.35% | 27,512,053 | - |
| 2 Re-Election of Director - Mr Geoffrey Kempler | P | 393,912,798 | 326,330,105 82.84% | 42,974,739 10.91% | 2,862,414 | 24,607,954 6.25% | 376,435,438 89.75% | 42,974,739 10.25% | 2,862,414 | Carried |
| 3 Ratification of prior issue of shares (Placement July 2024) | P | 292,690,098 | 184,971,185 63.20% | 82,614,126 28.23% | 1,286,814 | 25,104,787 8.58% | 253,554,351 75.42% | 82,614,126 24.58% | 1,286,814 | Carried |
| 4 Approval for issue of options - Mr Geoffrey Kempler | P | 336,743,973 | 251,964,801 74.82% | 63,859,918 18.96% | 57,757,839 | 20,919,254 6.21% | 298,381,434 82.37% | 63,859,918 17.63% | 57,757,839 | Carried |
| 5 Approval for issue of options - Mr Lawrence Gozlan | P | 337,583,973 | 251,873,001 74.61% | 64,288,385 19.04% | 57,194,439 | 21,422,587 6.35% | 316,773,967 83.13% | 64,288,385 16.87% | 57,194,439 | Carried |
| 6 Approval for issue of options - Mr Peter Marks | P | 337,356,373 | 251,667,001 74.60% | 64,266,785 19.05% | 57,953,639 | 21,422,587 6.35% | 309,381,999 82.80% | 64,266,785 17.20% | 57,953,639 | Carried |
| 7 Approval for issue of options - Mr Brian Meltzer | P | 330,247,116 | 244,620,144 74.07% | 64,204,385 19.44% | 57,941,639 | 21,422,587 6.49% | 309,521,110 82.82% | 64,204,385 17.18% | 57,941,639 | Carried |
| 8 Approval of 10% Placement Issue | P | 391,033,484 | 266,912,465 68.26% | 99,500,946 25.45% | 5,255,128 | 24,620,073 6.30% | 335,010,917 77.10% | 99,500,946 22.90% | 5,255,128 | Carried |